Summary
- ATTR-CM is a fatal disease that is frequently undiagnosed or misdiagnosed, and clinicians should know the “red flag” signs and symptoms
- Certain patient populations are at high risk of ATTR-CM, including those who have HFpEF*
- In patients with suspected ATTR-CM, initial assessment should include ECG, echocardiography, cardiac MRI, cardiac biomarkers, and functional status
- Diagnosis is based on testing for monoclonal protein followed by scintigraphy or biopsy
- TTR gene sequencing and genetic counseling are recommended in all cases of confirmed ATTR-CM
